AnneEBendelMD

Clinical Trials

• Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma Start of enrollment: 2007 Dec 17

  Active, not recruiting

  Phase 2

• Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG) Start of enrollment: 2011 Sep 01

  Terminated

  Phase 2

• A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma Start of enrollment: 2013 Jun 23

  Active, not recruiting

  Phase 2

• Laser Interstitial Thermal Therapy (LITT) for the Treatment of Pediatric Central Nervous System Tumors Start of enrollment: 2015 Apr 01

  Completed

  Not Applicable

• REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma Start of enrollment: 2018 Sep 24

  Terminated

  Phase 1, Phase 2

  Roles: Contact

• Fimepinostat in Treating Brain Tumors in Children and Young Adults Start of enrollment: 2019 Aug 07

  Active, not recruiting

  Early Phase 1

  Roles: Contact

• HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Start of enrollment: 2015 Sep 01

  Active, not recruiting

  Phase 4

  Roles: Contact

• Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors Start of enrollment: 2014 May 14

  Active, not recruiting

  Phase 2

  Roles: Contact, Principal Investigator

• Combination Therapy for the Treatment of Diffuse Midline Gliomas Start of enrollment: 2021 Oct 20

  Recruiting

  Phase 2

  Roles: Contact

• Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021) Start of enrollment: 2020 Dec 09

  Recruiting

  Phase 1

  Roles: Contact, Principal Investigator

• Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma Start of enrollment: 2022 Dec 20

  Recruiting

  Phase 2

  Roles: Principal Investigator, Contact

• CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults Start of enrollment: 2024 Mar 15

  Recruiting

  Phase 1

  Roles: Contact

• Join now to see all